Haemonetics Corp (FRA:HAZ)
€ 79 1 (1.28%) Market Cap: 3.99 Bil Enterprise Value: 4.87 Bil PE Ratio: 33.69 PB Ratio: 4.65 GF Score: 28/100

Haemonetics Corp at JPMorgan Healthcare Conference Transcript

Jan 10, 2023 / 10:15PM GMT
Release Date Price: €69 (+3.76%)
Unidentified Analyst

Hey, everyone. How's it going? My name is (inaudible). I cover medical devices and supplies here at JPMorgan. I'd just like to introduce Chris Simon, CEO of Haemonetics.

Christopher A. Simon
Haemonetics Corporation - CEO, President & Director

Thanks, (inaudible). Good afternoon and welcome. We're obviously very pleased to be back at JPMorgan, especially here in person after the time away. So I'm excited to provide you a look at where Haemonetics is today, where we are headed, including some unique opportunities that will enable an even greater impact across the markets we serve and help us deliver significant value, both for customers and ultimately for shareholders.

My remarks here today will have forward-looking non-GAAP numbers involved. So typical risk factors apply. You can refer to our SEC filings for any more information or questions you may have.

Back in June, we shared our updated long-range plan for transformational growth. Strong performance this year to date is evidence that our plan is working, and we are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot